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. Initial treatment for severe LRIs usually involves empirical broad-spectrum antibiotics. Guidelines recommend that such therapy should be refined or stopped after 2 to 3 days, once microbiology results become available 7, 8 , but this is often not done if the patient is responding well or the laboratory has failed to identify a pathogen. Such extensive 'blind' use of broad-spectrum antibiotics is wasteful and constitutes poor stewardship, given that many patients are infected with susceptible bacteria or a virus. Antimicrobial therapy disrupts resident gut flora and can contribute to the emergence of resistant bacteria and Clostridium difficile 9, 10 . Rapid and accurate microbiological diagnostics could enable tailored treatments and reduce overuse of broad-spectrum antibiotics. 'Gold standard' culture and susceptibility testing is too slow, with typical turnaround times of 48-72 h and low clinical sensitivity 4, 11 . Molecular methods may help overcome the limitations of culture, as highlighted by the UK Government 5-year AMR action plan and the O'Neill report [12] [13] [14] , by identifying pathogens and their antibiotic resistance profiles in a few hours, enabling early targeted therapy and supporting antibiotic stewardship. Although nucleic acid amplification tests (including PCR) are rapid and highly specific/sensitive, there are limits on multiplexing [15] [16] [17] [18] [19] , and there is also a constant need to update PCR-based methods to include emerging resistance genes and mutations 16, 20, 21 . Metagenomic sequencing-based approaches have the potential to overcome the shortcomings of both culture and PCR, by combining speed with comprehensive coverage of all microorganisms present 22, 23 . Next-generation sequencing platforms, such as Ion Torrent and Illumina, are widely used for metagenomics sequencing, but they require the sequencing run to be complete before analysis can begin (although LiveKraken, a recently described method, enables analysis of raw Illumina data before the run ends 24 ). Nanopore sequencing (Oxford Nanopore Technologies, ONT) has the advantage of rapid library preparation and real-time data acquisition 25, 26 . Nanopore sequencing has been used to identify viral and bacterial pathogens from clinical samples using targeted approaches and in proof-of-concept studies using samples with high pathogen loads, for example, urinary tract infection [26] [27] [28] .
Respiratory specimens present a difficult challenge for metagenomics sequencing due to variable pathogen load, the presence of commensal respiratory tract flora, and the high ratio of host:pathogen nucleic acids present (up to 10 5 :1 in sputum). Nanopore sequencing has previously been used for samples from two bacterial pneumonia patients without host cell/DNA depletion, but the vast majority of reads were of human origin, with only one and two reads aligned to the infecting pathogens, P. aeruginosa and S. aureus, respectively 29 . It seems likely that a metagenomics method would be improved by introducing host DNA depletion. Although commercial kits and published methods are available for this purpose (which include differential lysis, human DNA removal and microbial DNA enrichment methods [30] [31] [32] [33] ), they do not perform well in complex respiratory samples, and better methods are needed 34 . We present an optimized nanopore sequencing-based clinical metagenomics framework for bacterial LRIs that removes up to 99.99% of host nucleic acid from clinical respiratory samples and enables pathogen and antibiotic resistance gene identification within 6 h.
Results
Pilot method development. A pilot method was tested on respiratory samples from 40 patients with suspected bacterial LRI. This method was 91.4% sensitive (95% CI; 75.8-97.8% (all 95% CI values calculated throughout from http://vassarstats.net/clin1.html)) and 100% specific (95% confidence interval (CI); 46.3-100%), not counting additional organisms in culture-positive samples as false positives (Table 1) , and took 8 h to perform (Fig. 1) . Up to 99.9% or ~10 3 fold (median 352-fold, interquartile range 144-714; maximum 1,024-fold) of host DNA was removed using saponin depletion, as measured by quantitative PCR (qPCR). Microorganisms, including potential respiratory pathogens (Methods), were identified in realtime using ONT's 'What's In My Pot?' (WIMP) pipeline. Additional pathogens, not reported by microbiological culture, were detected in 5 out of 40 samples: Moraxella catarrhalis was detected in P8; Escherichia coli in P14; H. influenzae in P22 and P30; Klebsiella pneumoniae and M. catarrhalis in P29 (Table 1) .
Organisms cultured using routine clinical microbiology were not detected in 3 out of the 40 sequenced samples. Two of three samples were mixed infections, where one of the two pathogens present was missed by our pilot method-specifically, S. pneumoniae and H. influenzae were not detected in P3 and P37, respectively. S. aureus was not detected in the third sample, P34.
Metagenomics protocol optimization.
We sought to increase sensitivity (8.6% false negative rate) by improving bacterial cell lysis. A sample pre-treatment step was introduced (bead-beating or an enzyme cocktail, Methods) to optimize lysis. Two culture-positive sputa were used for optimization experiments, one containing S. aureus (Gram-positive) and one containing P. aeruginosa (Gramnegative). Neither pre-treatment affected the bacterial DNA yield in the P. aeruginosa sample. The enzyme cocktail increased the amount of bacterial DNA in the S. aureus sample by approximately fourfold, and bead-beating by 21-fold, compared with the pilot method, as determined by 16S qPCR (Supplementary Table 1a ). The increased bacterial DNA yield in the bead-beaten S. aureus sample was likely to have been associated with improved lysis of S. aureus, as the pathogen dominated the bacterial community (approximately 80% of reads) present in the sample. We included bead-beating in the optimized method. Removal of the second DNase treatment and reducing the number of washes shortened the host DNA removal protocol from 90 min to 50 min, without affecting efficiency (Supplementary Table 1a ). Additional time was saved by reducing the library preparation PCR extension time from 6 to 4 min. Comparison of the microbial community profile (organisms with ≥0.5% classified reads) between libraries produced with 4-and 6-min extension times showed only minor differences in the abundance of minor members of the community and a small reduction in average read length for the S. aureus sample (<600 base pairs (bp)) (Supplementary Table 1b) . Altogether, these changes reduced metagenomic library preparation to 2.5 h with an overall turnaround time of less than 4 h before DNA sequencing.
Limit of detection.
The limit of detection (LoD) of the optimized method was determined using uninfected 'normal respiratory flora' (NRF) sputum samples (high and low commensal bacterial backgrounds in triplicate) spiked with serial tenfold dilutions of S. aureus and E. coli cultures at known cell densities. Each replicate was defined as positive for the spiked 'pathogen' if present at ≥1% classified microbial reads (low-quality read alignments with a WIMP assignment q-score < 20 were removed from the analysis). The LoD (≥2/3 replicates positive) was determined to be 100,000 (10 5 ) cells for E. coli and 10,000 (10 4 ) cells for S. aureus when in a high bacterial background (Supplementary Table 2a Table 2 ). The overall sensitivity of the optimized method for the detection of respiratory pathogens was 96.6% (95% CI, 80.4-99.8%) and specificity was 41.7% (95% CI, 16.5-71.4%), not counting additional organisms in culture-positive samples as false positives ( Table 2 ). The turnaround time from sample to result was approximately 6 h, including 2 h MinION sequencing (Supplementary Table 4 ). The pathogenic organism reported by routine microbiology was detected together with an additional pathogen (not reported by culture) in eight samples: K. pneumoniae in S5, P. aeruginosa in S7, M. catarrhalis in S14 and S39, S. pneumoniae in S8 and S15, S. aureus in S29 and S. pyogenes in S27 (Table 2 ). Up to two potentially pathogenic bacteria were also observed in seven samples reported as NRF/no significant growth (NSG) by routine microbiology, that is, H. influenzae and S. pneumoniae in S10 and S21; S. pneumoniae in S11 and S28; M. catarrhalis and H. influenzae in S12; H. influenzae in S31 and E. coli in S32. Only one pathogenic organism reported by routine microbiology was not detected using the optimized method, that is, S9. This was reported as a mixed infection with P. aeruginosa and E. coli, whereas only E. coli was detected by metagenomics. There were three other mixed infections reported by routine microbiology, S27, S38 and S41, and both organisms were detected in all three samples using the optimized method.
Confirmatory qPCR was used to establish the presence or absence of the missed/additional pathogens detected by metagenomics in 16 samples (one sample with a missed pathogen, 15 samples with additional pathogen(s); total of 19 pathogens) and in matched controls, that is, an equal number of samples with no evidence of the pathogen by culture or metagenomics (Supplementary Table 5 ). This analysis was performed on DNA extracted from samples that did not undergo the depletion process, to rule out depletion as a potential cause of missed/additional pathogen detection. The majority of additional pathogens detected by metagenomics (12 out of 19) were confirmed by qPCR, which increased the specificity of the optimized method to 83.3% (95% CI, 36.5-99.1%-not counting additional organisms in culture-positive samples as false positives (n = 2, S5 positive for K. pneumoniae, likely k-mer misclassification of K. oxytoca. S41 positive for E. coli, likely laboratory/kit contamination)). qPCR was negative for P. aeruginosa (S9), increasing the sensitivity to 100% (95% CI, 87.7-100%).
Species-specific gene analysis was performed on all samples positive for pathobionts (potentially pathogenic organisms that may reside as commensals in the lung), that is, H. influenzae and S. pneumoniae, which can have closely related non-pathogenic species present in the lungs (18 samples containing 20 pathobionts). This confirmatory analysis was used to identify k-mer misclassification of commensal reads as pathogen reads by WIMP. Samples containing >1 H. influenzae (siaT) or S. pneumoniae (ply) specific gene alignments were considered positive for that organism. The pathobiont-specific gene analysis confirmed the absence of H. influenzae/S. pneumoniae in 5 out of 18 samples (also negative by qPCR, see previous paragraph) and resulted in metagenomics test sensitivity of 100% (95% CI, 87.7-100%) and specificity of 100% (95% CI, 51.7-100%) compared with the culture + qPCR gold standard (Supplementary Table 6 ).
Antibiotic resistance. The samples tested using the optimized method had little antibiotic resistance, based on routine testing (Supplementary Table 7 ). Across the 33 cultivated organisms, just 43 instances of resistance and intermediate resistance were recorded (Supplementary Table 7) , with some of these likely reflecting single underlying mechanisms. Sequencing identified 183 resistance genes across the 41 specimens (with multiple inclusions when Antimicrobial Resistance Mapping Application (ARMA) identified multiple variants of, for example, bla TEM ).
Among the 183 resistance genes, 26 were inherent to the species cultivated (for example, oqxA/B for K. pneumoniae or bla in P. aeruginosa), leaving 157, of which 24 matched the phenotype seen (Table 3 ). These comprised mecA in both MRSA (S16 and S40), sul1 and dfrA12 or dfrA17 in both co-trimoxazole-resistant E. coli (S1 and S9), aac(3')-IIa (and IIc) in a tobramycin-resistant E. coli (S9) and a total of 13 bla TEM variants recorded across two amoxicillin-resistant E. coli (S1 and S35) and two amoxicillin-resistant H. influenzae (S18 and S36). A caveat regarding this is that although ARMA flagged multiple bla TEM genes, it did not flag bla TEM-1 , which was the likeliest variant, given (1) that it is considerably the most prevalent type and (2) that the isolates remained susceptible to oxyimino-cephalosporins, whereas many of the variants flagged should encode extended-spectrum variants. Depending on their species, where β-lactam resistance most often reflects up-regulation of chromosomal ampC or efflux. There were 14 out of 183 genes where any associated resistance could not be confirmed because no relevant drug(s) was tested by the clinical laboratory; for example, tet genes were identified in several samples (S2, S8, S9, S16, S30, S35, S38 and S39) but tetracycline was not tested against the isolates cultured. Sixteen genes detected by ARMA did not match the phenotype of isolates cultured, which remained susceptible to relevant antibiotics, and 42 genes were unlikely to be from species grown by the laboratory. Finally, multiple genes (56 out of 183) likely originated from the normal flora: thus, tet(M) and bla TEM-4 were each found in 8 out of 12 NRF/NSG specimens, whilst mefA and mel were each found in 9 out of 12 as well as in many where the isolates grown were unlikely to have hosted these genes. There were nine samples where phenotypic resistances remained unexplained by resistance genes found by ARMA. These included two amoxicillin-resistant M. catarrhalis (S8 and S26), where the BRO β-lactamase genes were likely to be responsible but were not represented in the ARMA database. The remaining seven samples included ampicillin-and co-trimoxazole-resistant H. influenzae (S7, S18, S36, S39 and S41), trimethoprim-, ciprofloxacin-, gentamicin-and fusidic acid-resistant S. aureus (S16) and a K. pneumoniae (S2) resistant to both co-amoxiclav and piperacillin/tazobactam but lacking any acquired β-lactamase gene.
The specificity and sensitivity of the developed method for resistance gene detection were not determined, as this would have required isolating and sequencing all bacteria (pathogens and commensals) present-a prohibitive task.
Reference-based genome assembly. Two samples containing antibiotic-resistant bacteria were chosen as examples to generate reference-based genome assemblies directly from the metagenomic data. This analysis was performed to illustrate that whole pathogen genomes can be generated directly from respiratory samples for public health and infection control applications. Assemblies were generated for an MRSA (S16) and an E. coli resistant to amoxicillin, co-amoxiclav and co-trimoxazole (S1). The results were compared with those for undepleted controls after 2 and 48 h of sequencing. Within the first 2 h of sequencing, the human DNA depleted MRSA sample had 47.9× genome coverage with an assembly of 28 contigs (GCA_900660255: longest contig = 479 kbp and N50 = 400 kbp). Genome coverage increased to 228.7× after 48 h of sequencing, with a final assembly consisting of 22 contigs (GCA_900660245: longest contig = 481 kbp and N50 = 403 kbp). In contrast, the undepleted MRSA sample had an assembly of 69 contigs with 3.9× coverage (GCA_900660235: longest contig = 47 kbp and N50 = 146 kbp) after 2 h and 33 contigs (17.5× coverage) after 48 h (GCA_900660205: longest contig = 416 kbp and N50 = 263 kbp) (Fig. 2a) .
For the sample positive for resistant E. coli there was 33.5× genome coverage within 2 h for the depleted sample, with an assembly of 83 contigs (GCA_900660265: longest contig = 437 kbp and N50 = 165 kbp). Genome coverage increased to 165.7× after 48 h with the final E. coli assembly having 72 contigs (GCA_900660275: longest contig = 474 kbp and N50 = 178 kbp). The undepleted sample only produced 0.2× coverage after 2 h, which increased to 1.1× after 48 h of sequencing (Fig. 2b) .
Time-point analysis.
Using the same sample set as for genome assembly, data from the first 2 h of sequencing were compared over time for depleted samples and undepleted controls to highlight the importance of host depletion for turnaround time to result. Within 5 min of sequencing, the depleted MRSA sample (S16) had 1.6× genome coverage compared with 0.2× coverage for the undepleted control (Fig. 2c) . The mecA gene was not detected in the undepleted sample after 5 min, whereas two mecA gene alignments were detected in the depleted sample by the same time point (Fig. 2d) .
The depleted E. coli sample (S1) had 5.7× genome coverage within 20 min of sequencing compared with 0.06× for the undepleted control (Fig. 2e) . This E. coli was resistant to amoxicillin (bla TEM gene), co-amoxiclav (possibly due to bla TEM if strongly expressed) and cotrimoxazole (sul1 and dfrA17 genes). The bla TEM and dfrA17 genes were not detected in the undepleted sample within 2 h of sequencing, and only one alignment was detected for sul1. Conversely, all three resistance genes were detected within 20 min of sequencing in the depleted sample and, after 2 h, 47 bla TEM , 37 sulf1 and 21 dfrA17 alignments were detected (Fig. 2f) .
Discussion
Culture-based diagnostics and susceptibility testing, in use for 70 years 35 , have limitations as guides for the appropriate clinical management of acute infections, mainly because of their slow sampleto-result turnaround. Rapid, accurate diagnostics would enable treatment with appropriate antibiotics and improve health outcomes and antimicrobial stewardship alike. We developed a method to prepare respiratory samples for metagenomics sequencing and incorporated it into a nanopore metagenomic sequencing protocol for bacterial pathogen and antibiotic resistance gene identification in LRIs within 6 h of sample receipt.
Our metagenomics workflow for respiratory samples includes host DNA depletion, microbial DNA extraction, library preparation, MinION sequencing and real-time data analysis. A pipeline was developed (pilot method) and tested on 40 respiratory samples. We then optimized our method by shortening the depletion protocol, introducing bead-beating for improved microbial lysis and reducing the library preparation time. Mock community analysis demonstrated that the saponin-based human DNA depletion method did not inadvertently remove DNA from common respiratory pathogens, except for S. pneumoniae (mean 5.7-fold loss; Supplementary Table 3 ). It is possible that S. pneumoniae cells may have lysed during the host DNA depletion process 36 or might have lysed when grown to stationary phase for our mock community experiments. S. pneumoniae was correctly identified by metagenomics in five of six culture-positive patients, but it may have been underrepresented in these samples. The time from sample collection to bacterial DNA extraction may be crucial for accurate detection of S. pneumoniae.
The LoD of our optimized method (10 3 -10 5 c.f.u. ml -1 ) is within the range of culture-based clinical thresholds applied to respiratory samples. Our optimized method was 96.6% sensitive and 41.7% specific compared with culture. Discordant results were investigated using pathogen-specific probe-based qPCR assays (Supplementary  Table 5 ), which increased sensitivity (100%) and specificity (83.3%). Five of seven remaining discordant samples were positive for pathobionts, specifically H. influenzae and/or S. pneumoniae, by metagenomics. These false positive detections can be caused by misclassification of reads by WIMP, as k-mer-based read classification can be unreliable at the species level, particularly where species in a genus are highly related or share genes 37, 38 . To overcome this problem, we introduced post-hoc pathobiont-specific gene analysis for all H. influenzae and/or S. pneumoniae positive samples (n = 20 pathobionts in 18 samples). This analysis confirmed that the false positive results (n = 5) were caused by k-mer misclassification and resulted in metagenomics test sensitivity and specificity of 100% compared with culture + qPCR gold standard. This issue highlights the need for new methods to accurately identify bacterial species from metagenomic data 39 .
To maximize the impact on patient management, identification of clinically relevant antibiotic resistance genes as well as the infecting pathogen(s) is necessary. In this regard, the present pipeline has potential but requires refinement. Both MRSA cases were identified by the presence of mecA, with no false positives for this gene. Co-trimoxazole resistance in Enterobacteriaceae was accurately identified with detection of sul and dfr genes, and these were not found in H. influenzae, for which resistance is largely mutational 40, 41 . However, genes such as tet(M), mel, mefA and bla TEM were found in all samples where no pathogen was grown, suggesting presence in the normal or colonizing respiratory flora. To overcome this issue, it will be necessary to associate resistance genes to particular organisms. This can be done by examining flanking sequences [42] [43] [44] [45] in the approximately 3 kb nanopore reads in cases where a gene is chromosomally inserted (not plasmid-borne resistance genes), as is usual for transposon-borne tet(M) and mefA in streptococci [46] [47] [48] , including S. pneumoniae (Supplementary Fig. 1) .
Clinical metagenomics data could also be used to assemble pathogen genomes for reference laboratory typing. The quality/ depth of the metagenomic data generated by our method could enable monitoring of emergence and patient-to-patient spread of pathogens and antimicrobial resistance directly from clinical samples in real time 49, 50 . Using PCR for respiratory infection diagnosis must be coupled with microbiological culture-otherwise, the link to phenotype is lost-whereas clinical metagenomics could replace routine culture entirely. As viruses are an important cause of LRIs, they can be tested for using PCR, as is current routine practice, or our pipeline could be modified to detect viral nucleic acid by processing the supernatant fraction after centrifugation of the respiratory sample (Fig. 1, step 1 ).
In conclusion, we report a rapid clinical metagenomics pipeline for the characterization of bacterial LRIs. Pathogens and antibiotic resistance genes can be identified in 6 h. With additional sequencing time (up to 48 h), it provides sufficient data for public health and infection control applications. Our protocol is being evaluated in a clinical trial (INHALE, http://www.ucl.ac.uk/news/ news-articles/1115/181115-molecular-diagnosis-pneumonia) for the rapid diagnosis of hospital-acquired and ventilator-associated pneumonia in comparison with culture and multiplex-PCR.
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Methods
Ethics. This study used excess respiratory samples, after routine microbiology diagnostic tests had been performed, from patients with suspected LRIs such as persistent (productive) cough, bronchiectasis, CAP/HAP, cystic fibrosis and exacerbation of chronic obstructive pulmonary disease (COPD, emphysema/ chronic bronchitis). The UCL Infection DNA Bank (REC reference 12/LO/1089) approved use of excess respiratory samples for the study. No patient identifiable information was collected; hence, informed consent was not required. The only data collected were routine microbiology results, which detailed the pathogen(s) identified and their antibiotic susceptibility profiles.
Definitions. 'Respiratory pathogens' or 'pathogens' are defined in this study as common causes of respiratory infection to differentiate them from commensal organisms. Respiratory pathogens identified in this study were: E. aerogenes, E. cloacae complex, E. coli, H. influenzae, K. oxytoca, K. pneumoniae, M. catarrhalis, P. mirabilis, P. aeruginosa, S. marcescens, S. aureus, S. pneumoniae and S. pyogenes. A list of all microorganisms identified in all samples tested using the optimized method (above our thresholds) is provided in Supplementary Table 8 . Some of these organisms, not defined as common pathogens here, could be considered pathogens in some clinical contexts.
Routine clinical microbiological investigation. Respiratory samples including sputum, endotracheal secretions and ETAs were treated with sputasol (Oxoid-SR0233) in a 1:1 ratio before being incubated for a minimum of 15 min at 37 °C. Sputasol-treated respiratory samples (10 µl) were inoculated into 5 ml of sterile water and mixed (hence, the LoD of culture is 10 5 c.f.u. ml -1 ). Following this, 10 µl of sample was streaked onto blood, chocolate and cysteine lactose electrolyte deficient (CLED) agar. BAL samples were not treated with sputasol; instead, they were centrifuged to concentrate bacterial cells for a minimum of 10 min at 3,000 r.p.m. BALs did not undergo further dilution and were streaked directly onto the agar plate. Depending on clinical details and the source of the specimen, other agar plates (including sabouraud, mannitol salt and Burkholderia cepacia selective agar) were additionally used.
All inoculated agar plates were incubated at 37 °C overnight and then examined for growth with the potential for re-incubation up to 48 h. If any relevant organism was grown, then antibiotic susceptibility testing by agar diffusion using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology was performed. The laboratory's Standard Operating Procedure is based on the Public Health England UK Standards for Microbiology Investigations B 57: Investigation of bronchoalveolar lavage, sputum and associated specimens 51 .
Sample collection and storage. The excess respiratory samples (sputa, ETA and BAL) were collected after culture and susceptibility testing at Norfolk and Norwich University Hospitals (NNUH) Microbiology Department (described above) and stored at 4 °C before testing. They were indicated by clinical microbiology to contain bacterial pathogen(s) or NRF or to have yielded NSG. Forty samples (n = 34 positive and n = 6 NRF samples, comprising 34 sputa, four BALs and two ETAs) were used to test the pilot method and another 41 (n = 29 suspected LRI, n = 9 NRF and n = 3 NSG samples, comprising 38 sputa, one BAL and two ETAs) were used to test the optimized pipeline.
Pilot method: host DNA depletion. Respiratory samples (400 µl) were centrifuged at 8,000g for 5 min, after which the supernatant was carefully removed and the pellet resuspended in 250 µl of PBS. The saponin-based differential lysis method was modified from previously reported saponin methods 33, 52 . Saponin (Tokyo Chemical Industry, S0019) was added to a final concentration of 2.5% (200 µl of 5% saponin), mixed well and incubated at room temperature for 10 min to promote host cell lysis. Following this incubation, 350 µl of water was added and incubation was continued at room temperature for 30 s, after which 12 µl of 5 M NaCl was added to deliver an osmotic shock, lysing the damaged host cells. Samples were next centrifuged at 6,000g for 5 min, with the supernatant removed and the pellet resuspended in 100 µl of PBS. HL-SAN buffer (5.5 M NaCl and 100 mM MgCl 2 in nuclease-free water) was added (100 µl) with 5 µl of HL-SAN DNase (25,000 units, Articzymes, 70910-202) and incubated for 15 min at 37 °C with shaking at 800 r.p.m. for host DNA digestion. An additional 2 µl of HL-SAN DNase was added to the sample, which next was incubated for a further 15 min at 37 °C with shaking at 800 r.p.m. Finally, the host DNA depleted samples were washed three times with decreasing volumes of PBS (300 µl, 150 µl, 50 µl). After each wash, the sample was centrifuged at 6,000g for 3 min, the supernatant discarded and the pellet resuspended in PBS.
Pilot method: bacterial lysis and DNA extraction. After the final wash step of the host depletion, the pellet was resuspended in 380 µl of bacterial lysis buffer (Roche UK, 4659180001) and 20 µl of proteinase K (>600 milli-Anson units ml Optimized method: host DNA depletion (Fig. 1) . The optimized method sought to improve and shorten some steps. Specifically, after the first 5 min centrifugation at 8,000g, up to 50 µl of supernatant was left so as not to disturb the pellet (final saponin concentration 2.2-2.5%). Instead of performing two rounds of host DNA digestion, the amount of HL-SAN DNase was increased up to 10 µl and a single incubation of 15 min at 37 °C was carried out with shaking at 800 r.p.m. on an Eppendorf Thermomixer. Finally, the number of washes was reduced to two with increasing volumes of PBS (800 µl and 1 ml).
Optimized method: bacterial lysis and DNA extraction (Fig. 1) . After the final wash, the pellet was resuspended in 500 µl of bacterial lysis buffer (Roche UK, 4659180001), transferred to a bead-beating tube (Lysis Matrix E, MP Biomedicals, 116914050) and bead-beaten at maximum speed (50 oscillations per second) for 3 min in a Tissue Lyser bead-beater (Qiagen, 69980). This ensured the release of DNA from difficult-to-lyse organisms (for example, S. aureus). The sample was centrifuged at 20,000g for 1 min and ~230 µl of supernatant was transferred to a fresh Eppendorf tube. The volume was topped up with 170 µl of bacterial lysis buffer and 20 µl of proteinase K (>600 milli-Anson units ml DNA quantification and quality control. DNA quantification was performed using the high-sensitivity dsDNA assay kit (Thermo Fisher, Q32851) on the Qubit 3.0 Fluorometer (Thermo Fisher, Q33226). DNA quality and fragment size (PCR products and MinION libraries) were assessed using the TapeStation 2200 (Agilent Technologies, G2964AA) automated electrophoresis platform with the Genomic ScreenTape (Agilent Technologies, 5067-5365) and a DNA ladder (200 to >60,000 bp, Agilent Technologies, 5067-5366).
MinION library preparation and sequencing. MinION library preparation was performed according to the manufacturer's instructions for (1) the Rapid LowInput by PCR Sequencing Kit (SQK-RLI001), (2) the Rapid Low-Input Barcoding Kit (SQK-RLB001) or (3) the Rapid PCR Barcoding Kit (SQK-RPB004) with minor alterations as follows. For single sample sequencing runs using the SQK-RLI001 kit, 10 ng of the MagNA Pure-extracted DNA was used for the tagmentation/ fragmentation reaction, where DNA was incubated at 30 °C for 1 min and at 75 °C for 1 min. The PCR reaction was run as per the manufacturer's instructions; however, the number of PCR cycles was increased to 20. For multiplexed runs, SQK-RLB001 and SQK-RPB004 kits were used. A 1.2× AMPure XP bead (Beckman Coulter, A63881) wash was introduced after the MagNA Pure DNA extraction and before library preparation for multiplexed runs, and DNA was eluted in 15 µl of nuclease-free water. Modifications for the library preparation were (1) 10 ng of input DNA and 2.5 µl of FRM were used for the tagmentation/ fragmentation reaction and nuclease-free water was used to make the volume up to 10 µl, and (2) for the PCR reaction, 25 cycles were used and the reaction volume was doubled. All samples run using the pilot method used a 6 min extension time, whereas the optimized method used a reduced extension time of 4 min. When multiplexing, PCR products were pooled together in equal concentrations, then subjected to a 0.6× AMPure XP bead wash and eluted in 14 µl of the buffer recommended in the manufacturer's instructions (10 μl of 50 mM NaCl, 10 mM Tris.HCl pH 8.0). Sequencing was performed on the MinION platform using R9.4, R9.5 or R9.4.1 flow cells. The library (50-300 fmol) was loaded onto the flow cell according to the manufacturer's instructions. ONT MinKNOW software (v.1.4-1.13.1) was used to collect raw sequencing data, and ONT Albacore (v.1.2.2-2.1.10) was used for local base-calling of the raw data after sequencing runs were completed. The MinION was run for up to 48 h with WIMP/ARMA analysis performed on the first six folders (~24,000 reads) for pilot method samples and the first 2 h of data for all optimized method samples. qPCR assays. Probe-or SYBR-Green-based qPCR was performed on samples to detect and quantify human DNA, DNA targets for specific pathogens (E. coli, H. influenzae, K. pneumoniae, M. catarrhalis, P. aeruginosa, S. aureus, Stenotrophomonas maltophilia, S. pneumoniae and S. pyogenes) and the bacterial 16S rRNA V3-V4 gene fragment. All qPCR assays were performed on a LightCycler 480 Instrument (Roche). Details of primer sequences and targets can be found in Supplementary Table 9 (oligonucleotides were supplied by Sigma).
For all probe-based qPCR reactions, the master mix consisted of 10 µl of LightCycler 480 probe master (2×), 0.5 µl each of the reverse and forward primer (final concentration 0.25 µM) and 0.4 µl of probe (final concentration 0.2 µM). For all SYBR-Green-based qPCR reactions, the master mix consisted of 10 µl of LightCycler 480 SYBR Green I master (2×) and 1 µl of each of the forward and reverse primer (final concentration 0.5 µM). To the PCR mix, 2 µl of DNA template and nuclease-free water to a total volume of 20 µl were added. The qPCR conditions were: pre-incubation at 95 °C for 5 min, amplification for 40 cycles at 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, with a final extension at 72 °C for 5 min. Melt curve analysis (for SYBR-Green qPCR) was performed at 95 °C for 5 s, 65 °C for 1 min, ramping to 95 °C at 0.03 °C s -1 in continuous acquisition mode, followed by cooling to 37 °C. All probe-based confirmatory qPCR used the following conditions: pre-incubation at 95 °C for 15 min, amplification for 40 cycles at 94 °C for 15 s and 60 °C for 1 min.
Example limit of detection. The LoD of the optimized method was determined for the detection of one Gram-positive and one Gram-negative bacterium in sputum using serial dilutions (10 -10 5 c.f.u. ml -1 ) of cultured E. coli (H141480453) and S. aureus (NCTC 6571) spiked into NRF sputum samples with high and low bacterial commensal backgrounds (as determined by 16S qPCR). The serial dilutions were made in sterile PBS and plated in triplicate on Luria-Bertani (LB) agar to determine c.f.u. per ml. The same dilutions were used to spike an NRF sputum sample for LoD experiments. Detection and quantification of bacterial DNA were performed using probe-based qPCR assays and MinION sequencing.
Mock community experiments. Clinical isolates from respiratory samples were used to generate a mock community consisting of S. pneumoniae, K. pneumoniae, H. influenzae, S. maltophilia and P. aeruginosa. E. coli and S. aureus strains were also included (H141480453 and NCTC 6571, respectively). Pathogens (E. coli and S. aureus in 10 ml of LB broth and K. pneumoniae, P. aeruginosa and S. maltophilia in 10 ml of tryptic soy broth (TSB)) were cultured overnight at 37 °C with shaking at 180 r.p.m. H. influenzae (in 10 ml of TSB) and S. pneumoniae (in 10 ml of brain heart infusion broth) were cultured statically at 37 °C with 5% CO 2 in an aerobic incubator. Cultured pathogens were then spiked into an NRF sample (~10 3 -10 6 c.f.u. per pathogen). The spiked samples were then tested in triplicate with the optimized method to determine whether saponin depletion resulted in any inadvertent lysis of pathogens and loss of their DNA. All spiked samples were processed alongside undepleted controls. Probe-or SYBR-Green-based qPCR assays were used to determine the relative quantity of each spiked pathogen in depleted and undepleted spiked sputum samples.
Human read removal. Human reads were removed from basecalled FASTQ files using minimap2 to align to the human hg38 genome (GCA_000001405.15 'softmasked' assembly) before Epi2ME analysis. Only unassigned reads were exported to a bam file using Samtools (-f 4 parameter). Non-human reads were converted back to FASTQ format using bam2fastx. These FASTQ files were processed for pathogen identification using WIMP and antibiotic resistance gene detection with ARMA. Further downstream analysis for genome coverage was performed using minimap2 with default parameters for long-read data (-a -x map-ont) and visualized using qualimap (used for time-point analysis).
Pathogen identification and antibiotic resistance gene detection. The EPI2ME Antimicrobial Resistance pipeline (ONT, v.2.59.1896509) was used for initial analysis of MinION data for the identification of bacteria present in the sample and any associated antimicrobial resistance genes. Within this pipeline, WIMP rev. 3.3.1 supports the identification of bacteria, viruses, fungi, archaea and human reads and was used for respiratory pathogen identification. WIMP utilizes Centrifuge, a k-mer-based read identification tool based on a BurrowsWheeler transform and the Ferragina-Manzini index, to identify reads using the RefSeq database 53 . ARMA rev. 1.1.5 is also included in the Antimicrobial Resistance pipeline. ARMA utilizes the CARD database for antibiotic resistance gene detection and identification by aligning input reads using minimap2 (alignments reported at >75% accuracy and >40% horizontal coverage 54 ). Full manuals are publicly available for WIMP and ARMA on the ONT website (https:// nanoporetech.com/EPI2ME-amr). NanoOK/NanoOK RT 45, 55 are publically available tools that identify microbes and antimicrobial resistance using basecalled nanopore data, providing similar outputs to those from ONT's WIMP and ARMA software.
Initial analysis of respiratory metagenomic data revealed that thresholds would be required to improve the accuracy of results. Thresholds, in terms of number of bacteria per ml of body fluid, are applied in clinical microbiology laboratories for some infections, including those of the urinary and respiratory tracts. The same approach was required for metagenomics. The clinical threshold used for respiratory samples is typically 10 5 pathogens per ml (range 10 3 -10 5
per ml dependent on sample type) and is achieved by sample dilution 51 . We routinely applied thresholds at ≥1% of classified reads, with a WIMP assignment q-score ≥ 20 (within .csv files). We chose these thresholds to censor reads arising from pipeline contaminants; remove barcode leakage between samples on multiplexed runs (ONT's Flongle (https://nanoporetech.com/products/ comparison), an adapter for single use flow cells designed for diagnostic applications, should overcome this issue); and remove low-quality WIMP alignments, which result in misclassified reads. Antibiotic resistance genes were reported if >1 gene alignment was present using the 'clinically relevant' parameter within ARMA. This parameter currently reports resistance genes, acquired and chromosomal, but not resistance mutations/SNPs.
Pathobiont-specific gene analysis. Species-specific gene alignments were performed on samples positive for H. influenzae or S. pneumoniae by metagenomics (above our thresholds). Reads (after human DNA removal) were aligned to pathobiont-specific genes (siaT and ply-chosen from a literature search for species-specific genes in H. influenzae 56 and S. pneumoniae 15 , respectively) using minimap2 with default parameters for long-read data (-a -x map-ont) and the number of mapped reads visualized using qualimap. If a sample contained >1 copy of the specific gene it was considered positive for the species.
Bacterial genome assembly. Genome assembly was performed first using Fast5-to-Fastq to remove reads shorter than 2,000 bp and with a mean quality score lower than seven (https://github.com/rrwick/Fast5-to-Fastq). Porechop was used to remove sequencing adapters in the middle and/or the ends of each read, and re-identification of barcodes was carried out for each multiplexed sample (v.0.2.3) (https://github.com/rrwick/Porechop). Filtered reads were aligned to a reference genome (chosen based on WIMP classification of pathogen reads) using minimap2 with default parameters for ONT long-read data (v.2.6-2.10) 57 . Finally, Canu was used to assemble mapped reads into contigs using this longread sequence correction and assembly tool (v.1.6) 58, 59 . BLAST Ring Image Generator (BRIG) was used for BLAST comparisons of the genome assemblies generated 60 .
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Sample size
This is a proof-of-concept study designed to demonstrate the application of metagenomics to the diagnosis of respiratory infection. A total of 81 samples were tested, a sample size sufficient to provide confidence in the efficacy of the method. Larger studies will be required to accurately determine clinical performance. This sample size is consistent with other proof-of-concept clinical metagenomics studies recently published in the literature e.g. Langelier, C. et al. PNAS 115, E12353 (2018), with a sample size of 91.
Data exclusions No data was excluded from this study.
Replication
Limit of detection and mock community experiments were performed in triplicate (see paper for results). Time point analysis, genome assembly and resistance gene host identification experiments were performed using three independent clinical samples (results of 2 clinical samples for each experiment are shown in the paper -the third sample for each experiment produced similar results). Clinical samples were tested once and compared to the standard of care (microbiological culture). Insufficient sample volume was available for replication.
Randomization Excess respiratory samples from patients with suspected lower tract infection were collected from the hospital Clinical Microbiology laboratory in a random fashion, on different days and times, collecting different sample types (sputum, BAL, ETAs) and sample numbers over the course of the study.
Blinding
Microbiological culture and antibiogram results were not made available to the academic researchers until after metagenomic output was analysed.
Reporting for specific materials, systems and methods Obtaining unique materials This study used excess respiratory samples, after routine microbiology diagnostic tests had been performed and sample material is no longer available.
